CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Fluoxetine

· ingredient fluoxetine· FLUOXETINE HYDROCHLORIDE 10 mg/1; FLUOXETINE HYDROCHLORIDE 20 mg/1; FLUOXETINE HYDROCHLORIDE 40 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.03640
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 11 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other fluoxetine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Fluoxetine$0.05206+$0.01570
Fluoxetine$0.06677+$0.03040
Fluoxetine$0.07791+$0.04150
fluoxetine$0.08905+$0.05270
Fluoxetine$0.20220+$0.16580
fluoxetine$0.22711+$0.19070
Olanzapine and Fluoxetine$4.47+$4.44
Fluoxetine Hydrochloride$30.35+$30.31

Medicare Part D coverage · CY2026

On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 30% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.